{"classes":[{"categories":[{"measurements":[{"comment":"Median OS for group 1 has not been attained.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median OS for group 2 has not been attained.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"OS was defined as the time from registration to death of any cause. Participants were followed for a maximum of 5 years from randomization. The median OS with 95%CI was estimated using the Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Lenalidomide 25 mg PI days 1-21 Cyclophosphamide 300 mg/m\\^2 PO days 1, 8, 15 Dexamethasone 40 mg PI days 1, 8, 15, 22","id":"OG000","title":"LCD (Cyclophosphamide 300 mg/m^2)"},{"description":"Lenalidomide 25 mg PI days 1-21 Cyclophosphamide 300 mg PO days 1, 8, 15 Dexamethasone 40 mg PI days 1, 8, 15, 22","id":"OG001","title":"LCD (Cyclophosphamide 300 mg)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to 5 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}